Labcorp Holdings (LH)
NYSE:LH
Want to see LH full AI Analyst Report?
Top Page
Labcorp Holdings
(NYSE:LH)
Select Model
Select Model
Rating:65Neutral
Price Target:
$276.00
▲(1.97% Upside)
Action:ReiteratedDate:04/30/26
The score is driven by improving fundamentals and cash flow plus a notably positive earnings update with raised/narrowed guidance and margin expansion expectations. These positives are tempered by weak technical momentum (below key moving averages with negative MACD and low RSI) and only moderate valuation support given a ~23.8 P/E and ~1.12% dividend yield.
Positive Factors
Diversified Business Model & Scale
Labcorp's combined diagnostics and drug‑development platforms create durable, recurring demand from health systems, payers and biopharma sponsors. Scale and geographic breadth strengthen pricing leverage, referral relationships and ability to invest in specialty assays and trial services over the medium term.
Negative Factors
Regulatory & Reimbursement Risk
Potential regulatory changes to reimbursement formulas and access represent structural downside for diagnostics revenue and mix. Sustained policy shifts could compress pricing or restrict volumes for routine and specialty tests, pressuring margins and requiring strategic repositioning over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified Business Model & Scale
Labcorp's combined diagnostics and drug‑development platforms create durable, recurring demand from health systems, payers and biopharma sponsors. Scale and geographic breadth strengthen pricing leverage, referral relationships and ability to invest in specialty assays and trial services over the medium term.
Read all positive factors
Labcorp Holdings (LH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$21.16B
Dividend Yield1.14%
Average Volume (3M)544.70K
Price to Earnings (P/E)19.8
Beta (1Y)0.35
Revenue Growth7.34%
EPS Growth30.39%
CountryUS
Employees60,900
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)11.37
Shares Outstanding82,000,000
10 Day Avg. Volume535,796
30 Day Avg. Volume544,695
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)2.42
Price to Sales (P/S)1.50
P/FCF Ratio17.31
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue1.92
Enterprise Value/Gross Profit6.89
Enterprise Value/Ebitda13.06
Forecast
1Y Price Target
$310.78Price Target Upside14.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)18.01
Revenue Forecast (FY)$14.69B
Labcorp Holdings Business Overview & Revenue Model
Company Description
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC....
How the Company Makes Money
Labcorp primarily makes money by delivering two broad categories of services: (1) clinical laboratory and diagnostic testing and (2) drug development services for life sciences customers. In its clinical diagnostics business, revenue is generated ...
Labcorp Holdings Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down sales across various business divisions, revealing which segments are contributing most to the top line and where there might be potential for expansion or risk.
Breaks down sales across various business divisions, revealing which segments are contributing most to the top line and where there might be potential for expansion or risk.
Data provided by:
The Fly
The FlyLabcorp Holdings Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call presented a predominately positive picture: solid top-line growth, double-digit EPS improvement, margin expansion, healthy BLS backlog and raised/narrowed guidance. Management highlighted strong progress on strategic partnerships, product launches and AI/technology initiatives. Key challenges include weather-driven volume disruption, Early Development transitional actions, regulatory/reimbursement uncertainty (CRUSH, PAMA/RESULTS Act), and modest short-term cash flow/leverage considerations. Overall, positives around organic growth, profitability and a robust deal/product pipeline outweigh the identified headwinds.Positive Updates
Enterprise Revenue Growth
Q1 enterprise revenue of $3.5 billion, up ~5.8% year-over-year (management cited ~6%), driven primarily by organic growth in Diagnostics and Central Labs.
Negative Updates
Weather-Related Volume Disruption
Adverse weather estimated to have reduced Q1 revenue by about $15 million; management noted organic Dx volume would have been closer to ~2% without the weather impact and that weather remains difficult to predict and not explicitly baked into forecasts.
Read all updates
Q1-2026 Updates
Positive
Negative
Enterprise Revenue Growth
Q1 enterprise revenue of $3.5 billion, up ~5.8% year-over-year (management cited ~6%), driven primarily by organic growth in Diagnostics and Central Labs.
Read all positive updates
Company Guidance
Labcorp updated its full‑year 2026 outlook, raising the midpoint of enterprise revenue by about $30 million and EPS midpoint by $0.13 while narrowing the EPS range; enterprise revenue is now guided to grow 5.0%–6.1% (FX assumed at March 31, 2026, with ~40 bps FX tailwind), Diagnostics revenue 5.1%–5.9% (midpoint ~5.5%), and Biopharma Lab Services (BLS) revenue 3.8%–5.4% (including ~150 bps FX tailwind); on an organic constant‑currency basis Central Labs are expected to grow mid‑single digits while Early Development is expected to be roughly flat with a stronger H2. Adjusted EPS is guided to $17.70–$18.35 (midpoint implying ~10% growth), adjusted tax rate around 23% for the year, free cash flow $1.24B–$1.36B (weighted to the second half), capital expenditures ~4% of revenue, and continued enterprise margin expansion (with BLS margin expected to expand more than Diagnostics); guidance reflects continued use of free cash flow for acquisitions, share repurchases and dividends and assumes the company’s stated M&A pipeline and launchpad initiatives.Labcorp Holdings Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
68
Positive
Cash Flow
73
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.14B | 13.95B | 13.01B | 12.16B | 11.86B | 13.14B |
| Gross Profit | 3.93B | 3.73B | 3.62B | 3.36B | 3.71B | 4.99B |
| EBITDA | 2.08B | 2.01B | 1.81B | 1.35B | 1.95B | 3.68B |
| Net Income | 941.50M | 876.50M | 746.00M | 418.00M | 1.28B | 2.38B |
Balance Sheet | ||||||
| Total Assets | 19.09B | 18.39B | 18.38B | 16.73B | 20.16B | 20.39B |
| Cash, Cash Equivalents and Short-Term Investments | 981.10M | 532.30M | 1.52B | 536.80M | 320.60M | 1.47B |
| Total Debt | 7.24B | 7.20B | 7.27B | 5.95B | 6.25B | 6.34B |
| Total Liabilities | 10.34B | 9.76B | 10.31B | 8.83B | 10.04B | 10.09B |
| Stockholders Equity | 8.73B | 8.62B | 8.05B | 7.88B | 10.10B | 10.27B |
Cash Flow | ||||||
| Free Cash Flow | 1.38B | 1.21B | 1.10B | 874.10M | 1.47B | 2.65B |
| Operating Cash Flow | 1.81B | 1.64B | 1.59B | 1.33B | 1.96B | 3.11B |
| Investing Cash Flow | -1.18B | -1.19B | -1.37B | -1.17B | -1.65B | -884.60M |
| Financing Cash Flow | -36.80M | -1.46B | 779.90M | -59.30M | -1.32B | -2.07B |
Labcorp Holdings Technical Analysis
Positive
270.68
Price Trends
273.35
Negative
267.29
Positive
267.11
Positive
Market Momentum
-0.80
Negative
51.65
Neutral
50.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LH, the sentiment is Positive. The current price of 270.68 is above the 20-day moving average (MA) of 267.92, below the 50-day MA of 273.35, and above the 200-day MA of 267.11, indicating a neutral trend. The MACD of -0.80 indicates Negative momentum. The RSI at 51.65 is Neutral, neither overbought nor oversold. The STOCH value of 50.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LH.
Labcorp Holdings Risk Analysis
Labcorp Holdings disclosed 44 risk factors in its most recent earnings report. Labcorp Holdings reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Labcorp Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $28.25B | 21.12 | 7.55% | ― | 2.11% | -7.88% | |
70 Outperform | $21.13B | 21.39 | 14.11% | 1.80% | 11.03% | 14.34% | |
69 Neutral | $20.96B | 32.31 | 10.21% | 0.94% | 7.96% | 53.16% | |
68 Neutral | $11.11B | 40.30 | 21.38% | ― | 31.93% | -24.86% | |
65 Neutral | $21.16B | 19.76 | 10.91% | 1.14% | 7.34% | 30.39% | |
65 Neutral | $29.82B | 26.20 | 22.46% | ― | 7.33% | 9.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
LH
Labcorp Holdings
258.05
14.93
6.14%
BIIB
Biogen
191.38
73.21
61.95%
PODD
Insulet
160.40
-150.27
-48.37%
DGX
Quest Diagnostics
190.84
17.02
9.79%
STE
Steris
213.70
-10.49
-4.68%
IQV
IQVIA Holdings
178.64
29.65
19.90%
Labcorp Holdings Corporate Events
Dividends
Labcorp Declares Quarterly Cash Dividend, Signals Ongoing Confidence
Positive
Apr 9, 2026
Labcorp Holdings Inc., a global leader in laboratory diagnostics and drug development services, provides testing and scientific insights to healthcare providers, pharmaceutical firms, researchers and patients in roughly 100 countries, with nearly ...
Financial Disclosures
Labcorp Sets Date for First-Quarter 2026 Results
Neutral
Apr 1, 2026
Labcorp Holdings Inc., a major global laboratory services provider, plans to release its financial results for the first quarter of 2026 before the U.S. market opens on Thursday, April 30, 2026, and will host a webcast at 9:00 a.m. ET that day to ...
Private Placements and Financing
Labcorp Holdings Secures New $750 Million Term Loan
Positive
Mar 20, 2026
On March 20, 2026, Labcorp Holdings Inc. and its subsidiary Laboratory Corporation of America Holdings entered into a new term loan credit agreement providing a $750 million senior unsecured term loan maturing on March 20, 2028. The facility, full...
Executive/Board Changes
Labcorp Holdings Adds John Sampson to Board
Positive
Feb 9, 2026
Labcorp Holdings Inc., the Burlington, N.C.-based provider of diagnostic and drug development laboratory services, has expanded its board with the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, effective February 9, 2026. Sampson, vice ch...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.